Literature DB >> 1168991

Tetanus and diphtheria antitoxin levels following a hospital-based adult immunization program.

J D Thorley, R K Holmes, J P Sanford.   

Abstract

A hospital-based program to immunize adults against tetanus unless specific contraindications to immunization are present has been in effect at Parkland Memorial Hospital since 1959. Adsorbed tetanus toxoid was used from 1959 to 1970, and was replaced at that time by adult type adsorbed combined tetanus/diphtheria toxoid. In the present survey, the titers of diphtheria and tetanus antitoxins were determined in sera from 97 adults admitted to the Medical Service. Titers of diphtheria antitoxin less than 0.0125 units per ml were found in only seven patients and less than 0.0125 units per ml of tetanus antitoxin in only 17 patients. This high prevalence of immunity especially to tetanus appears to reflect our practice of routine immunization of adults. Although the recommended frequency of tetanus boosters has recently been reduced for adults who have completed a full primary immunization series, susceptibility to diphtheria or tetanus or both is not uncommon among adults in the US. Unless contraindications are present, we therefore urge routine immunization of all adults seeking medical care and of all hospital personnel as a means of diminishing the risk of diphtheria and tetanus in those adult populations with a significant incidence of susceptibility to these diseases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1168991     DOI: 10.1093/oxfordjournals.aje.a112111

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  2 in total

1.  Preventive medicine and public health-epitomes of progress: diphtheria and tetanus immunization for older adults.

Authors:  L Dales
Journal:  West J Med       Date:  1982-01

2.  Epidemiology of tetanus in the Marches Region of Italy, 1992-95.

Authors:  E Prospero; R Appignanesi; M M D'Errico; F Carle
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.